Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gardasil 9 booster response after 2 vs 3 doses of Q-HPV vaccine
NCT02968420Phase 4Completed
- Sponsor
- University of British Columbia
- Start
- Sep 2017
- Primary completion
- May 2019
- Countries
- 1
01
Overview
Phase 4, open-label trial of recombinant human papillomavirus 9-valent vaccine in human papillomavirus infection (3 arms), sponsored by University of British Columbia. Primary endpoints: B Memory Cell Response (% of Memory B Cells That Are Antigen-specific) at 30 days and Plasmablast Response (% of All B Cells That Are Plasmablasts) at 7 days. Started Sep 2017; status: completed.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on NCT02968420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02968420.